The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression
- PMID: 17100888
- DOI: 10.1111/j.1600-065X.2006.00445.x
The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression
Abstract
Tumor immunosurveillance relies on cognate immune effectors [lymphocytes and interferon-gamma (IFN-gamma)] and innate immunity [natural killer (NK) cells, natural killer group 2, member D (NKG2D) ligands, perforin/granzyme, and tumor necrosis factor-related apoptosis-inducing ligand]. In parallel, tumor cells promote the expansion of CD4(+)CD25(+) regulatory T cells (Tregs) that counteract T-cell-based anti-tumor immunity. Moreover, accumulating evidence points to a critical role for Tregs in dampening NK cell immune responses. This review summarizes the findings showing that Tregs suppress NK cell effector functions in vitro and in vivo, i.e. homeostatic proliferation, cytotoxicity, and interleukin-12-mediated IFN-gamma production. The molecular mechanism involve selective expression of membrane-bound transforming growth factor-beta on Tregs, which downregulate NKG2D expression on NK cells in vitro and in vivo. The regulatory events dictating NK cell suppression by Tregs have been studied and are discussed. The pathological relevance of the Treg-NK cell interaction has been brought up in tumor models and in patients with cancer. Consequently, inhibition of Tregs through pharmacological interventions should be considered during NK-cell-based immunotherapy of cancer.
Similar articles
-
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.J Exp Med. 2005 Oct 17;202(8):1075-85. doi: 10.1084/jem.20051511. J Exp Med. 2005. PMID: 16230475 Free PMC article.
-
Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.Exp Hematol. 2007 Mar;35(3):416-25. doi: 10.1016/j.exphem.2006.12.004. Exp Hematol. 2007. PMID: 17309822
-
Increase of regulatory T cells in the peripheral blood of cancer patients.Clin Cancer Res. 2003 Feb;9(2):606-12. Clin Cancer Res. 2003. PMID: 12576425
-
Multiple roles for CD4+ T cells in anti-tumor immune responses.Immunol Rev. 2008 Apr;222:129-44. doi: 10.1111/j.1600-065X.2008.00616.x. Immunol Rev. 2008. PMID: 18363998 Review.
-
Porcine T lymphocytes and NK cells--an update.Dev Comp Immunol. 2009 Mar;33(3):310-20. doi: 10.1016/j.dci.2008.06.003. Epub 2008 Jul 2. Dev Comp Immunol. 2009. PMID: 18601948 Review.
Cited by
-
Immunomodulation of NK Cells by Ionizing Radiation.Front Oncol. 2020 Jun 16;10:874. doi: 10.3389/fonc.2020.00874. eCollection 2020. Front Oncol. 2020. PMID: 32612950 Free PMC article. Review.
-
Lymphocyte Landscape after Chronic Hepatitis C Virus (HCV) Cure: The New Normal.Int J Mol Sci. 2020 Oct 10;21(20):7473. doi: 10.3390/ijms21207473. Int J Mol Sci. 2020. PMID: 33050486 Free PMC article. Review.
-
Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2.J Exp Med. 2013 Jun 3;210(6):1153-65. doi: 10.1084/jem.20122248. Epub 2013 May 6. J Exp Med. 2013. PMID: 23650440 Free PMC article.
-
Exploring the Interplay between Cellular Senescence, Immunity, and Fibrosing Interstitial Lung Diseases: Challenges and Opportunities.Int J Mol Sci. 2024 Jul 10;25(14):7554. doi: 10.3390/ijms25147554. Int J Mol Sci. 2024. PMID: 39062798 Free PMC article. Review.
-
3-Methylcholanthrene-induced transforming growth factor-beta-producing carcinomas, but not sarcomas, are refractory to regulatory T cell-depletion therapy.Cancer Sci. 2010 Apr;101(4):855-61. doi: 10.1111/j.1349-7006.2009.01469.x. Epub 2009 Dec 11. Cancer Sci. 2010. PMID: 20151983 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
